The global seasonal allergy market enjoys a valuation of US$ 1.15 Billion in 2022, and it is further projected to expand at a CAGR of 7.8% over the forecasted years. According to a recent study by Future Market Insights, tablets/capsules by form leading the market with a share of about 37.1% in the year 2022, within the global market.
Market Outlook
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 1.15 Billion |
| Market Value 2033 | US$ 2.58 Billion |
| CAGR 2023 to 2033 | 7.8% |
| Market Share of Top 5 Countries | 62.1% |
| Key Market Players | Merck KGaA, Johnson & Johnson, Allergopharma, Sanofi SA, McNeil Consumer Healthcare, Genentech Inc., GlaxoSmithKline PLC, Leti Pharma, Alerpharma S.A, Allergan, Inc., Meda Pharmaceuticals, Inc, Novartis International AG, Bausch Health Companies Inc., Allergopharma, ALK Abello, Stallergenes, Greer, Allergy Therapeutics, Aimmune Therapeutics, Biomay AG, HAL Allergy Group, Bayer, AstraZeneca |
Seasonal allergies, like other allergies, develop when the body's immune system overreacts to a trigger in the environment, usually in the spring, summer, or fall when specific plants pollinate. A growing number of producers have identified allergies as a viable market, and with the help of a research and development team, they are delivering fresh, cutting-edge therapy and treatment options to the market, expanding the range of already available treatments. A large portion of people are still affected by seasonal allergies yearly.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global sales of the market are anticipated to rise at a CAGR of 7.8% between 2023 and 2033, owing to the rising prevalence of allergic diseases.
The global market holds around 5.7%share of the overall global allergy treatment market with a value of around US$ 20.2 Million, in 2022.
Longer pollen seasons during warmer temperatures or higher carbon dioxide emissions brings about higher quantities of pollen. These are the key contributors to the seasonal allergies affecting an individual. The incidence rate and prevalence rate of seasonal allergies are growing rapidly owing to which the demand for available treatments is expected to increase over the forecast period.
Antihistamines, decongestants, nasal corticosteroids, allergen immunotherapy, and leukotriene receptor antagonists are some of the most well-liked treatments for seasonal allergies. Antihistamines dominate the market since they are one of the most widely used and widely prescribed medications for the treatment of allergies, both with and without a prescription.
Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around US$ 2.58 Billion during the year 2033.
This creates an enormous opportunity for the manufacturer to explore the seasonal allergy market. Several biopharma businesses with tested technology and cutting-edge treatment choices that are unique and have been approved have emerged as a result of the life science industry's entry into the pharmaceutical sector. This enables medical professionals to rely on these novel treatment possibilities.
For instance, allergy immunotherapy as a treatment has proven to be successful in multiple clinical trials. Such as high-dose, standardized vaccinations are used in subcutaneous injection immunotherapy (SCIT). These medications typically contain 5–20 mcg of the main allergen. SCITs are given as maintenance injections every month. Also, sublingual allergy immunotherapy (SLIT) involves the sublingual space's unique, tolerance-promoting immune cells, also known as oral Langerhans cells. Liquid antigens (drops) and pills are the two therapeutic options for SLIT.
Overall, it is anticipated that the market for seasonal allergies will rise over the coming years as more research and development are put into creating fresh, efficient treatment choices.
Principal Consultant
The market is experiencing a decline due to the adverse effects associated with allergy shots and tablets.
Periodic injections are administered over time as allergy shots. Immunotherapy for allergies is a protracted treatment that might last anywhere between three and five years. It entirely depends on the kind and degree of allergy.
Each allergy shot contains a very small amount of the exact ingredients or substances that cause allergic responses.
Patients frequently discontinue therapy in the middle of the procedure due to extended treatment schedules, age, health, physical location, and financial constraints.
The time associated with the treatment may hinder market growth.
The USA dominates the North American region with a global market share of around 30.8% in 2022. In the United States, the importance of artificial intelligence (AI) in medical sciences cannot be overstated. The healthcare industry in the US is one of the largest in the world, and it faces numerous challenges, such as rising costs, an aging population, and a shortage of healthcare professionals.
AI has the potential to address many of these challenges by improving the accuracy and efficiency of medical diagnosis and treatment. For instance, in the case of seasonal allergies, AI The Weather Channel data science team has been trying to develop a tool to assist seasonal allergy sufferers as spring progresses and summer draws closer. Allergy Insights with Watson, a new service that uses AI to assist forecast seasonal allergy risk in the United States, is freely accessible on The Weather Channel app and weather.com.
In order to aware people in making the more appropriate decisions and preparing for allergy season, united states in going to witness an exponential growth in the global market
China has a market share of 9.5%, with a market value of US$ 109.9 Million in the global seasonal allergy market in 2022.
In China, allergy immunotherapy (AIT) has been practiced for more than 60 years. The Chinese College of Allergy and Asthma (CCAA), a specialized branch of CDMA that serves as the primary certifying body for AIT, was formed in 2016 with the backing of the Chinese Medical Association (CMA) and the Chinese Medical Doctors Association (CMDA). Chinese allergists and researchers have made significant advancements in the creation of AIT. Chinese allergists and researchers have published a large number of articles globally that include original research investigations, systematic reviews, case studies, and clinical trials. Sublingual immunotherapy (SLIT) is starting to gain popularity in China, where traditional subcutaneous immunotherapy (SCIT) is now the favored AIT.
Similar to the United States, immunotherapy is popular in China and it is expected to establish a steady growth in the coming years.
Germany holds a market share of 8.7% in 2022 in the global seasonal allergy market, owing to the presence of many established players in European countries.
Germany is a global leader in biotechnology, and the environment for the growth of commercial biotechnology is only improving. This has a favorable impact on the growth of new businesses that specialize in this industry. There were more businesses between 2015 and 2019 by 20.7%. Germany continues to be the top European nation for funding the biotechnology sector. 78% of the industry's overall budget in 2019 was generated through venture capital and initial public offerings (IPOs). About 70% of all businesses in Germany use biotechnology for medical purposes, which is particularly significant in light of the recent developments brought on by COVID-19.
Germany is strengthening its manufacturing and development of novel drugs which will positively grow the market in the future.
India holds a share of around 6.6% in the global market in 2022.
The prevalence of allergies and asthma is increasing in India, and it has turned into a serious health issue. Symptoms can range from mild rhinitis to severe asthma, and even life-threatening anaphylaxis. This subcontinent has a very broad "allergen repertoire" because of its distinct climatic conditions, flora, and dietary customs. To make an accurate diagnosis and create immunotherapeutic vaccines, allergy-eliciting chemicals must be correctly identified, purified, and molecularly characterized. Although there are many reports on common allergies, the majority of these studies relied on early allergen detection and identification. Recombinant technologies and structural biology have only been used to characterize a small number of these allergen compounds.
There are still millions of cases of the disease worldwide, despite India's prevalence rates generally being lower than those of high-income countries. Due to the large number of patients, Indian biopharmaceutical companies must enhance their supply of treatment medications.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Tablets/Capsules are mostly favored by patients suffering from allergies. It has contributed US$ 427.4 Million to the global market in 2022.
Because of its durability and patient acceptability, the tablet is the most commonly utilized dosage form out of all those that are available. As a result, the coating plays a crucial role in the tablet's composition. The superior aesthetic qualities, such as color, texture, mouth feel, and flavor masking, depending on the film and sugar coatings. This makes tablets/capsules the most lucrative form.
OTC led the global market with over 76.0% value share in 2022. Customers find it simpler to buy OTC medications because they are widely accessible and may be purchased without a prescription. People can save time and money by not having to wait for prescriptions to be filled or make appointments with doctors. More people can afford OTC medications because they are often less expensive than prescription medicines.
Oral is mostly preferred by patients. It has a market share of 36.6% in the global market in 2022. Oral drugs are uncomplicated to administer, patients can take them at home without a doctor's supervision. Oral drugs are advantageous for those with chronic illnesses who require long-term care. Oral drugs are typically less expensive than those administered intravenously or orally, which necessitate more specialized equipment and physician oversight.
Antihistamines have a market share of 46.0% in the global market in 2022.
The ease of use and accessibility of over-the-counter antihistamines is high. Second-generation antihistamines are also thought to be a better option. However, each one must be assessed based on their particular efficacy and safety.
Hospital pharmacies hold a market share of 35.9% during the year 2022. Hospitals are the primary locations where readily available, licensed, and approved medication can be found. By collaborating with doctors, nurses, and pharmacy staff to provide the proper medications and supplies during treatment procedures, hospital pharmacies can significantly improve patient care. Hospitals can exceed their patient satisfaction goals with the guarantee of improved patient outcomes. Due to the extensive treatment offered in hospital settings, the category is predicted to expand at a profitable rate throughout the projection period.
Collaboration with scientific and research foundations to increase public awareness and receiving product approvals from regulatory bodies are the key strategies opted by key players within this market space.
Similarly, recent developments related to companies within the seasonal allergy market space have been tracked by the team at Future Market Insights. These are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2018 to 2022 |
| Historical Data Available for | 2023 to 2033 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, the United kingdom, Germany, Italy, Russia, Spain, France, Benelux, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa and South Africa |
| Key Market Segments Covered | Form, Prescription Type, Route of Administration, Treatment, Distribution Channel |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The seasonal allergy market is anticipated to go up from US$ 1.22 billion in 2023 to US$ 2.58 billion by 2033, exhibiting a CAGR of 7.8%.
With a 5.7% CAGR between 2018 and 2022, the seasonal allergy market size reached US$ 1.15 billion in 2022.
Given its prevalent allergenic flora and demand for effective treatments, the United States stands as the dominant market for seasonal allergy products.
Seasonal allergy market trends include rising allergen sensitization, personalized treatment demand, and improved allergy management methods.
Prominent market players such as Merck KGaA, Johnson & Johnson, Allergopharma, Sanofi SA, McNeil Consumer Healthcare, and Genentech Inc. dominate the seasonal allergy market.
1. Executive Summary | Seasonal Allergy Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value Added Insights
4.1. Disease Epidemiology
4.1.1. Prevalence Population
4.1.2. Diagnosed Prevalence Cases
4.1.3. Severity Specific Cases
4.2. Regulatory Guidelines
4.3. Patient Treatment Regime
4.4. PESTLE Analysis
4.5. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Global Life Expectancy Outlook
5.1.4. Pharmaceutical Spending
5.1.5. Global Allergy Treatment Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increase Prevalence of Seasonal Allergy
5.2.2. Diagnostic Rate (%)
5.2.3. Treatment Seeking Rate (%)
5.2.4. Cases treated with Allergic Conditions
5.2.5. Overall Cost of Treatment
5.2.6. Recent Advancements In Technology
5.2.7. Regulatory Framework
5.2.8. Key Strategic Developments By Market Players
5.2.9. Adverse Effects May Impact the Market Growth
5.2.10. Growing Investment in Healthcare Sector
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity
6. COVID-19 Crisis – Impact Assessment
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Form
6.1.2. Revenue By Prescription Type
6.1.3. Revenue By Route of Administration
6.1.4. Revenue By Treatment
6.1.5. Revenue By Distribution Channel
6.1.6. Revenue By Country
6.2. 2022 Market Scenario
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis, 2018 to 2022
7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Form
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis, By Form, 2018 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Form, 2023 to 2033
8.3.1. Tablets/Capsules
8.3.2. Liquid
8.3.3. Creams & Lotions
8.3.4. Drops
8.3.5. Spray
8.4. Market Attractiveness Analysis By Form
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Prescription Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis, By Prescription Type, 2018 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Prescription Type, 2023 to 2033
9.3.1. OTC
9.3.2. Prescription based
9.4. Market Attractiveness Analysis By Prescription Type
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis, By Route of Administration, 2018 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
10.3.1. Oral
10.3.2. Intranasal
10.3.3. Sublingual
10.3.4. Sub Cutaneous
10.3.5. Intravenous
10.4. Market Attractiveness Analysis By Route of Administration
11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis, By Treatment, 2018 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
11.3.1. Antihistamines
11.3.2. Decongestants
11.3.3. Nasal Corticosteroids
11.3.4. Allergen Immunotherapy
11.3.5. LeUnited kingdomotriene Receptor Antagonists
11.4. Market Attractiveness Analysis By Treatment
12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis, By Distribution Channel, 2018 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
12.3.1. Hospital Pharmacies
12.3.2. Supermarkets/Hypermarkets
12.3.3. Online Pharmacies
12.3.4. Retail Pharmacies
12.3.5. Specialty Clinics
12.3.6. Others
12.4. Market Attractiveness Analysis By Distribution Channel
13. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis By Region, 2018 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. East Asia
13.3.5. South Asia
13.3.6. Oceania
13.3.7. Middle East and Africa (MEA)
13.4. Market Attractiveness Analysis By Region
14. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. USA
14.3.1.2. Canada
14.3.2. By Form
14.3.3. By Prescription Type
14.3.4. By Route of Administration
14.3.5. By Treatment
14.3.6. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Form
14.4.3. By Prescription Type
14.4.4. By Route of Administration
14.4.5. By Treatment
14.4.6. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. USA Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Form
14.8.1.2.2. By Prescription Type
14.8.1.2.3. By Route of Administration
14.8.1.2.4. By Treatment
14.8.1.2.5. By Distribution Channel
14.8.2. Canada Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Form
14.8.2.2.2. By Prescription Type
14.8.2.2.3. By Route of Administration
14.8.2.2.4. By Treatment
14.8.2.2.5. By Distribution Channel
15. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Mexico
15.3.1.2. Brazil
15.3.1.3. Argentina
15.3.1.4. Rest of Latin America
15.3.2. By Form
15.3.3. By Prescription Type
15.3.4. By Route of Administration
15.3.5. By Treatment
15.3.6. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Form
15.4.3. By Prescription Type
15.4.4. By Route of Administration
15.4.5. By Treatment
15.4.6. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Mexico Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Form
15.8.1.2.2. By Prescription Type
15.8.1.2.3. By Route of Administration
15.8.1.2.4. By Treatment
15.8.1.2.5. By Distribution Channel
15.8.2. Brazil Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Form
15.8.2.2.2. By Prescription Type
15.8.2.2.3. By Route of Administration
15.8.2.2.4. By Treatment
15.8.2.2.5. By Distribution Channel
15.8.3. Argentina Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Form
15.8.3.2.2. By Prescription Type
15.8.3.2.3. By Route of Administration
15.8.3.2.4. By Treatment
15.8.3.2.5. By Distribution Channel
16. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. United kingdom
16.3.1.2. Germany
16.3.1.3. France
16.3.1.4. Italy
16.3.1.5. Spain
16.3.1.6. BENELUX
16.3.1.7. Russia
16.3.1.8. Rest of Europe
16.3.2. By Form
16.3.3. By Prescription Type
16.3.4. By Route of Administration
16.3.5. By Treatment
16.3.6. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Form
16.4.3. By Prescription Type
16.4.4. By Route of Administration
16.4.5. By Treatment
16.4.6. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. United kingdom Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Form
16.8.1.2.2. By Prescription Type
16.8.1.2.3. By Route of Administration
16.8.1.2.4. By Treatment
16.8.1.2.5. By Distribution Channel
16.8.2. Germany Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Form
16.8.2.2.2. By Prescription Type
16.8.2.2.3. By Route of Administration
16.8.2.2.4. By Treatment
16.8.2.2.5. By Distribution Channel
16.8.3. France Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Form
16.8.3.2.2. By Prescription Type
16.8.3.2.3. By Route of Administration
16.8.3.2.4. By Treatment
16.8.3.2.5. By Distribution Channel
16.8.4. Italy Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Form
16.8.4.2.2. By Prescription Type
16.8.4.2.3. By Route of Administration
16.8.4.2.4. By Treatment
16.8.4.2.5. By Distribution Channel
16.8.5. Spain Market Analysis
16.8.5.1. Introduction
16.8.5.2. Market Analysis and Forecast by Market Taxonomy
16.8.5.2.1. By Form
16.8.5.2.2. By Prescription Type
16.8.5.2.3. By Route of Administration
16.8.5.2.4. By Treatment
16.8.5.2.5. By Distribution Channel
16.8.6. BENELUX Market Analysis
16.8.6.1. Introduction
16.8.6.2. Market Analysis and Forecast by Market Taxonomy
16.8.6.2.1. By Form
16.8.6.2.2. By Prescription Type
16.8.6.2.3. By Route of Administration
16.8.6.2.4. By Treatment
16.8.6.2.5. By Distribution Channel
16.8.7. Russia Market Analysis
16.8.7.1. Introduction
16.8.7.2. Market Analysis and Forecast by Market Taxonomy
16.8.7.2.1. By Form
16.8.7.2.2. By Prescription Type
16.8.7.2.3. By Route of Administration
16.8.7.2.4. By Treatment
16.8.7.2.5. By Distribution Channel
17. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Form
17.3.3. By Prescription Type
17.3.4. By Route of Administration
17.3.5. By Treatment
17.3.6. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Form
17.4.3. By Prescription Type
17.4.4. By Route of Administration
17.4.5. By Treatment
17.4.6. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. China Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Form
17.8.1.2.2. By Prescription Type
17.8.1.2.3. By Route of Administration
17.8.1.2.4. By Treatment
17.8.1.2.5. By Distribution Channel
17.8.2. Japan Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Form
17.8.2.2.2. By Prescription Type
17.8.2.2.3. By Route of Administration
17.8.2.2.4. By Treatment
17.8.2.2.5. By Distribution Channel
17.8.3. South Korea Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Form
17.8.3.2.2. By Prescription Type
17.8.3.2.3. By Route of Administration
17.8.3.2.4. By Treatment
17.8.3.2.5. By Distribution Channel
18. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. India
18.3.1.2. Malaysia
18.3.1.3. Thailand
18.3.1.4. Indonesia
18.3.1.5. Rest of South Asia
18.3.2. By Form
18.3.3. By Prescription Type
18.3.4. By Route of Administration
18.3.5. By Treatment
18.3.6. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Form
18.4.3. By Prescription Type
18.4.4. By Route of Administration
18.4.5. By Treatment
18.4.6. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. India Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Form
18.8.1.2.2. By Prescription Type
18.8.1.2.3. By Route of Administration
18.8.1.2.4. By Treatment
18.8.1.2.5. By Distribution Channel
18.8.2. Malaysia Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Form
18.8.2.2.2. By Prescription Type
18.8.2.2.3. By Route of Administration
18.8.2.2.4. By Treatment
18.8.2.2.5. By Distribution Channel
18.8.3. Thailand Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Form
18.8.3.2.2. By Prescription Type
18.8.3.2.3. By Route of Administration
18.8.3.2.4. By Treatment
18.8.3.2.5. By Distribution Channel
18.8.4. Indonesia Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Form
18.8.4.2.2. By Prescription Type
18.8.4.2.3. By Route of Administration
18.8.4.2.4. By Treatment
18.8.4.2.5. By Distribution Channel
19. Oceania Market 2018 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. By Form
19.3.3. By Prescription Type
19.3.4. By Route of Administration
19.3.5. By Treatment
19.3.6. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Form
19.4.3. By Prescription Type
19.4.4. By Route of Administration
19.4.5. By Treatment
19.4.6. By Distribution Channel
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. Australia Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Form
19.8.1.2.2. By Prescription Type
19.8.1.2.3. By Route of Administration
19.8.1.2.4. By Treatment
19.8.1.2.5. By Distribution Channel
19.8.2. New Zealand Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Form
19.8.2.2.2. By Prescription Type
19.8.2.2.3. By Route of Administration
19.8.2.2.4. By Treatment
19.8.2.2.5. By Distribution Channel
20. Middle East and Africa (MEA) Market Analysis 2018 to 2022 and Forecast 2023 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
20.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
20.3.1. By Country
20.3.1.1. GCC Countries
20.3.1.2. Türkiye
20.3.1.3. South Africa
20.3.1.4. Israel
20.3.1.5. North Africa
20.3.1.6. Rest of Middle East and Africa
20.3.2. By Form
20.3.3. By Prescription Type
20.3.4. By Route of Administration
20.3.5. By Treatment
20.3.6. By Distribution Channel
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Form
20.4.3. By Prescription Type
20.4.4. By Route of Administration
20.4.5. By Treatment
20.4.6. By Distribution Channel
20.5. Market Trends
20.6. Key Market Participants - Intensity Mapping
20.7. Drivers and Restraints - Impact Analysis
20.8. Country Level Analysis & Forecast
20.8.1. GCC Countries Market Analysis
20.8.1.1. Introduction
20.8.1.2. Market Analysis and Forecast by Market Taxonomy
20.8.1.2.1. By Form
20.8.1.2.2. By Prescription Type
20.8.1.2.3. By Route of Administration
20.8.1.2.4. By Treatment
20.8.1.2.5. By Distribution Channel
20.8.2. Türkiye Market Analysis
20.8.2.1. Introduction
20.8.2.2. Market Analysis and Forecast by Market Taxonomy
20.8.2.2.1. By Form
20.8.2.2.2. By Prescription Type
20.8.2.2.3. By Route of Administration
20.8.2.2.4. By Treatment
20.8.2.2.5. By Distribution Channel
20.8.3. South Africa Market Analysis
20.8.3.1. Introduction
20.8.3.2. Market Analysis and Forecast by Market Taxonomy
20.8.3.2.1. By Form
20.8.3.2.2. By Prescription Type
20.8.3.2.3. By Route of Administration
20.8.3.2.4. By Treatment
20.8.3.2.5. By Distribution Channel
20.8.4. Israel Market Analysis
20.8.4.1. Introduction
20.8.4.2. Market Analysis and Forecast by Market Taxonomy
20.8.4.2.1. By Form
20.8.4.2.2. By Prescription Type
20.8.4.2.3. By Route of Administration
20.8.4.2.4. By Treatment
20.8.4.2.5. By Distribution Channel
20.8.5. North Africa Market Analysis
20.8.5.1. Introduction
20.8.5.2. Market Analysis and Forecast by Market Taxonomy
20.8.5.2.1. By Form
20.8.5.2.2. By Prescription Type
20.8.5.2.3. By Route of Administration
20.8.5.2.4. By Treatment
20.8.5.2.5. By Distribution Channel
21. Market Structure Analysis
21.1. Market Analysis by Tier of Companies
21.2. Market Share Analysis of Top Players
21.3. Market Presence Analysis
22. Competition Analysis
22.1. Competition Dashboard
22.2. Key Development Analysis
22.3. Branding and Promotional Strategies, by Manufacturers
22.4. Competition Deep Dive
22.4.1. Merck KGaA
22.4.1.1. Overview
22.4.1.2. Product Portfolio
22.4.1.3. Key Financials
22.4.1.4. SWOT Analysis
22.4.1.5. Key Developments
22.4.1.6. Sales Footprint
22.4.1.7. Strategy Overview
22.4.1.7.1. Marketing Strategies
22.4.1.7.2. Product Strategies
22.4.1.7.3. Channel Strategies
22.4.2. Johnson & Johnson
22.4.2.1. Overview
22.4.2.2. Product Portfolio
22.4.2.3. Key Financials
22.4.2.4. SWOT Analysis
22.4.2.5. Key Developments
22.4.2.6. Sales Footprint
22.4.2.7. Strategy Overview
22.4.2.7.1. Marketing Strategies
22.4.2.7.2. Product Strategies
22.4.2.7.3. Channel Strategies
22.4.3. Allergopharma
22.4.3.1. Overview
22.4.3.2. Product Portfolio
22.4.3.3. Key Financials
22.4.3.4. SWOT Analysis
22.4.3.5. Key Developments
22.4.3.6. Sales Footprint
22.4.3.7. Strategy Overview
22.4.3.7.1. Marketing Strategies
22.4.3.7.2. Product Strategies
22.4.3.7.3. Channel Strategies
22.4.4. Sanofi SA
22.4.4.1. Overview
22.4.4.2. Product Portfolio
22.4.4.3. Key Financials
22.4.4.4. SWOT Analysis
22.4.4.5. Key Developments
22.4.4.6. Sales Footprint
22.4.4.7. Strategy Overview
22.4.4.7.1. Marketing Strategies
22.4.4.7.2. Product Strategies
22.4.4.7.3. Channel Strategies
22.4.5. McNeil Consumer Healthcare,
22.4.5.1. Overview
22.4.5.2. Product Portfolio
22.4.5.3. Key Financials
22.4.5.4. SWOT Analysis
22.4.5.5. Key Developments
22.4.5.6. Sales Footprint
22.4.5.7. Strategy Overview
22.4.5.7.1. Marketing Strategies
22.4.5.7.2. Product Strategies
22.4.5.7.3. Channel Strategies
22.4.6. Genentech Inc.
22.4.6.1. Overview
22.4.6.2. Product Portfolio
22.4.6.3. Key Financials
22.4.6.4. SWOT Analysis
22.4.6.5. Key Developments
22.4.6.6. Sales Footprint
22.4.6.7. Strategy Overview
22.4.6.7.1. Marketing Strategies
22.4.6.7.2. Product Strategies
22.4.6.7.3. Channel Strategies
22.4.7. GlaxoSmithKline PLC
22.4.7.1. Overview
22.4.7.2. Product Portfolio
22.4.7.3. Key Financials
22.4.7.4. SWOT Analysis
22.4.7.5. Key Developments
22.4.7.6. Sales Footprint
22.4.7.7. Strategy Overview
22.4.7.7.1. Marketing Strategies
22.4.7.7.2. Product Strategies
22.4.7.7.3. Channel Strategies
22.4.8. Leti Pharma,
22.4.8.1. Overview
22.4.8.2. Product Portfolio
22.4.8.3. Key Financials
22.4.8.4. SWOT Analysis
22.4.8.5. Key Developments
22.4.8.6. Sales Footprint
22.4.8.7. Strategy Overview
22.4.8.7.1. Marketing Strategies
22.4.8.7.2. Product Strategies
22.4.8.7.3. Channel Strategies
22.4.9. Alerpharma S.A
22.4.9.1. Overview
22.4.9.2. Product Portfolio
22.4.9.3. Key Financials
22.4.9.4. SWOT Analysis
22.4.9.5. Key Developments
22.4.9.6. Sales Footprint
22.4.9.7. Strategy Overview
22.4.9.7.1. Marketing Strategies
22.4.9.7.2. Product Strategies
22.4.9.7.3. Channel Strategies
22.4.10. Allergan, Inc.
22.4.10.1. Overview
22.4.10.2. Product Portfolio
22.4.10.3. Key Financials
22.4.10.4. SWOT Analysis
22.4.10.5. Key Developments
22.4.10.6. Sales Footprint
22.4.10.7. Strategy Overview
22.4.10.7.1. Marketing Strategies
22.4.10.7.2. Product Strategies
22.4.10.7.3. Channel Strategies
22.4.11. Meda Pharmaceuticals, Inc
22.4.11.1. Overview
22.4.11.2. Product Portfolio
22.4.11.3. Key Financials
22.4.11.4. SWOT Analysis
22.4.11.5. Key Developments
22.4.11.6. Sales Footprint
22.4.11.7. Strategy Overview
22.4.11.7.1. Marketing Strategies
22.4.11.7.2. Product Strategies
22.4.11.7.3. Channel Strategies
22.4.12. Novartis International AG
22.4.12.1. Overview
22.4.12.2. Product Portfolio
22.4.12.3. Key Financials
22.4.12.4. SWOT Analysis
22.4.12.5. Key Developments
22.4.12.6. Sales Footprint
22.4.12.7. Strategy Overview
22.4.12.7.1. Marketing Strategies
22.4.12.7.2. Product Strategies
22.4.12.7.3. Channel Strategies
22.4.13. Bausch Health Companies Inc.
22.4.13.1. Overview
22.4.13.2. Product Portfolio
22.4.13.3. Key Financials
22.4.13.4. SWOT Analysis
22.4.13.5. Key Developments
22.4.13.6. Sales Footprint
22.4.13.7. Strategy Overview
22.4.13.7.1. Marketing Strategies
22.4.13.7.2. Product Strategies
22.4.13.7.3. Channel Strategies
22.4.14. Allergopharma
22.4.14.1. Overview
22.4.14.2. Product Portfolio
22.4.14.3. Key Financials
22.4.14.4. SWOT Analysis
22.4.14.5. Key Developments
22.4.14.6. Sales Footprint
22.4.14.7. Strategy Overview
22.4.14.7.1. Marketing Strategies
22.4.14.7.2. Product Strategies
22.4.14.7.3. Channel Strategies
22.4.15. ALK Abello
22.4.15.1. Overview
22.4.15.2. Product Portfolio
22.4.15.3. Key Financials
22.4.15.4. SWOT Analysis
22.4.15.5. Key Developments
22.4.15.6. Sales Footprint
22.4.15.7. Strategy Overview
22.4.15.7.1. Marketing Strategies
22.4.15.7.2. Product Strategies
22.4.15.7.3. Channel Strategies
22.4.16. Stallergenes Greer
22.4.16.1. Overview
22.4.16.2. Product Portfolio
22.4.16.3. Key Financials
22.4.16.4. SWOT Analysis
22.4.16.5. Key Developments
22.4.16.6. Sales Footprint
22.4.16.7. Strategy Overview
22.4.16.7.1. Marketing Strategies
22.4.16.7.2. Product Strategies
22.4.16.7.3. Channel Strategies
22.4.17. Allergy Therapeutics
22.4.17.1. Overview
22.4.17.2. Product Portfolio
22.4.17.3. Key Financials
22.4.17.4. SWOT Analysis
22.4.17.5. Key Developments
22.4.17.6. Sales Footprint
22.4.17.7. Strategy Overview
22.4.17.7.1. Marketing Strategies
22.4.17.7.2. Product Strategies
22.4.17.7.3. Channel Strategies
22.4.18. Aimmune Therapeutics
22.4.18.1. Overview
22.4.18.2. Product Portfolio
22.4.18.3. Key Financials
22.4.18.4. SWOT Analysis
22.4.18.5. Key Developments
22.4.18.6. Sales Footprint
22.4.18.7. Strategy Overview
22.4.18.7.1. Marketing Strategies
22.4.18.7.2. Product Strategies
22.4.18.7.3. Channel Strategies
22.4.19. Biomay AG
22.4.19.1. Overview
22.4.19.2. Product Portfolio
22.4.19.3. Key Financials
22.4.19.4. SWOT Analysis
22.4.19.5. Key Developments
22.4.19.6. Sales Footprint
22.4.19.7. Strategy Overview
22.4.19.7.1. Marketing Strategies
22.4.19.7.2. Product Strategies
22.4.19.7.3. Channel Strategies
22.4.20. HAL Allergy Group
22.4.20.1. Overview
22.4.20.2. Product Portfolio
22.4.20.3. Key Financials
22.4.20.4. SWOT Analysis
22.4.20.5. Key Developments
22.4.20.6. Sales Footprint
22.4.20.7. Strategy Overview
22.4.20.7.1. Marketing Strategies
22.4.20.7.2. Product Strategies
22.4.20.7.3. Channel Strategies
22.4.21. Bayer
22.4.21.1. Overview
22.4.21.2. Product Portfolio
22.4.21.3. Key Financials
22.4.21.4. SWOT Analysis
22.4.21.5. Key Developments
22.4.21.6. Sales Footprint
22.4.21.7. Strategy Overview
22.4.21.7.1. Marketing Strategies
22.4.21.7.2. Product Strategies
22.4.21.7.3. Channel Strategies
22.4.22. AstraZeneca
22.4.22.1. Overview
22.4.22.2. Product Portfolio
22.4.22.3. Key Financials
22.4.22.4. SWOT Analysis
22.4.22.5. Key Developments
22.4.22.6. Sales Footprint
22.4.22.7. Strategy Overview
22.4.22.7.1. Marketing Strategies
22.4.22.7.2. Product Strategies
22.4.22.7.3. Channel Strategies
23. Assumptions and Acronyms Used
24. Research Methodolog
Explore Healthcare Insights
View Reports
Seasonal Allergy Market
